A Johnson & Johnson unit working to resolve massive cancer litigation in bankruptcy court was accused by a former head of the US Food and Drug Administration of making misleading claims that the company’s baby powder never contained asbestos.

The cuts at the FDA’s device center could add “months, if not years” to the time it takes to bring products to market, an attorney said.

Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a Strong Buy rating for JNJ stock.

Medtech giants are doubling down on robotic surgery systems as hospitals see fewer complications and shorter stays.

A U.S. launch for Hugo would come amid a changing landscape for soft tissue robotics. Medtronic and Johnson & Johnson plan to take on Intuitive in the space, as well as a collection of smaller medtech firms with specialized machines. However, Wall Street ...

Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA subcutaneous, SC, induction therapy in adults with moderately to